Study S000269

Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07253285
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 460
Start: 2026-01-08
Primary completion: 2030-03-20
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1299-4751; OTHER:2023-509176-42; NIH:2023

Registered primary outcomes

Relative change in body mass index (BMI) [Baseline (week 0), week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.